Time is crucial in malignant tumor cases: Speeding up the process of patient-specific implant creation.
artificial intelligence
computer-aided design
head and neck squamous cell carcinoma
mandible
patient-specific implant
time-to-treatment
workflow
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
03
2022
accepted:
23
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
Patient-specific implants are commonly used to reconstruct lower jaw defects following surgical treatment for head and neck squamous cell carcinoma. The planning process of surgery is time-consuming and can delay the "time to surgery," which should be as short as possible. Therefore, this study aimed to evaluate the planning process to speed up and identify any sources of problems. In this retrospective study, we enrolled patients who underwent continuous resection of the mandible in combination with reconstruction with a patient-specific implant between 2016 and 2021. The predictor variables were in-house training of the engineers and implant complexity (complex [with additional features] vs. less complex [resembling standard reconstruction plates]). The outcome variables were the duration of communication, message length, and the need for synchronous communication or modifications to the original design. Descriptive and univariate statistics were computed, and statistical significance was set at P < 0.05. The data from 83 patients were included in this study. The mean duration of communication was 14.05 ± 13.58 days. The implant complexity and training status of the engineer had no statistically significant influence on the primary outcome variables. As for the secondary outcome variables, the implant complexity significantly influenced the chance that the planned operation had to be postponed (15/16 [93.75%] were complex cases, P = 0.001). The most frequent cause of problems in the planning process was an insufficient dataset, which was not dependent on the type of imaging. The overall duration of the patient-specific implant creation process is too long to meet oncological requirements. Therefore, standardization of the planning process to accelerate implant creation is of utmost importance. In addition, a common standard imaging format (independent of the type of imaging) for oncological cases could eliminate all delays caused by insufficient datasets in the future.
Identifiants
pubmed: 36212406
doi: 10.3389/fonc.2022.904343
pmc: PMC9533641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
904343Informations de copyright
Copyright © 2022 Spalthoff, Nejati-Rad, Rahlf, Jehn, Gellrich, Lentge and Korn.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Maxillofac Oral Surg. 2020 Dec;19(4):609-615
pubmed: 33071511
Eur J Surg Oncol. 2021 Aug;47(8):1816-1827
pubmed: 33715909
J Oral Maxillofac Surg. 2022 Apr;80(4):676-681
pubmed: 34995487
Acta Oncol. 2021 Sep;60(9):1083-1090
pubmed: 34043480
J Natl Compr Canc Netw. 2016 Jan;14(1):115-6
pubmed: 26733558
Int J Oral Maxillofac Surg. 2020 Jan;49(1):13-21
pubmed: 31230767
J Craniomaxillofac Surg. 2017 Nov;45(11):1884-1897
pubmed: 28965991
Oral Dis. 2021 Jan;27(1):14-20
pubmed: 32881177
Front Oncol. 2021 Nov 26;11:719028
pubmed: 34900674
PLoS One. 2017 Apr 7;12(4):e0175148
pubmed: 28388649
Acta Otorhinolaryngol Ital. 2021 Jun;41(3):230-235
pubmed: 34264916
J Craniomaxillofac Surg. 2020 Mar;48(3):315-322
pubmed: 32089430
J Craniomaxillofac Surg. 2016 Jul;44(7):795-9
pubmed: 27193477
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Ann Surg Oncol. 2021 Feb;28(2):877-885
pubmed: 33188461
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Comput Assist Radiol Surg. 2015 Dec;10(12):2035-51
pubmed: 25843949
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Clin Oncol. 2016 Jan 10;34(2):169-78
pubmed: 26628469